Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(11), P. 1362 - 1362
Published: Oct. 25, 2024
Cationic
vaccines
of
nanometric
sizes
can
directly
perform
the
delivery
antigen(s)
and
immunomodulator(s)
to
dendritic
cells
in
lymph
nodes.
The
positively
charged
nanovaccines
are
taken
up
by
antigen-presenting
(APCs)
lymphatic
system
often
originating
cellular
immunological
defense
required
fight
intracellular
microbial
infections
proliferation
cancers.
molecules
imparting
positive
charges
exhibit
a
dose-dependent
toxicity
which
needs
be
systematically
addressed.
Against
coronavirus,
mRNA
cationic
evolved
rapidly.
Nowadays
have
been
formulated
against
several
with
advantage
compounds
granting
protection
nucleic
acids
vivo
biodegradation
nucleases.
Up
threshold
concentration
for
nanovaccine
delivery,
well
eliciting
desired
Th
1
improved
immune
response
absence
cytotoxicity.
A
second
strategy
literature
involves
dilution
components
biocompatible
polymeric
matrixes.
Polymeric
nanoparticles
incorporating
at
reduced
concentrations
component
result
an
toxic
effects.
progress
vaccinology
cancer
situ
designs
nanovaccines.
lysis
transformed
releases
tumoral
antigens,
presence
nanoadjuvants
systemically
presented
prevention
metastatic
cancer.
In
addition,
these
local
allow
immunotherapeutic
tumor
treatment.
Angewandte Chemie International Edition,
Journal Year:
2024,
Volume and Issue:
64(1)
Published: Aug. 23, 2024
Chalcogens
are
used
as
sensitive
redox-responsive
reagents
in
tumor
therapy.
However,
chalcogen
bonds
triggered
by
external
ionizing
radiation,
rather
than
internal
environmental
stimuli,
enable
site-directed
and
real-time
drug
degradation
target
lesions.
This
approach
helps
to
bypass
chemoresistance
global
systemic
toxicity,
presenting
a
significant
advancement
over
traditional
chemoradiotherapy.
In
this
study,
we
fabricated
hybrid
monodisperse
organosilica
nanoprodrug
based
on
homonuclear
single
(disulfide
(S-S,
approximately
240
kJ/mol),
diselenium
(Se-Se,
172
tellurium
(Te-Te,
126
kJ/mol)),
including
ditelluride-bond-bridged
MONs
(DTeMSNs),
diselenide-bond-bridged
(DSeMSNs)
disulfide-bond-bridged
(DSMSNs).
The
results
demonstrated
that
differences
electronegativities
atomic
radii
influenced
their
oxidation
sensitivities
reactivities.
Tellurium,
with
the
lowest
electronegativity,
showed
highest
sensitivity,
followed
selenium
sulfur.
DTeMSNs
exhibited
highly
responsive
cleavage
upon
exposure
X-rays,
resulting
TeO
Chemical Communications,
Journal Year:
2024,
Volume and Issue:
60(71), P. 9550 - 9553
Published: Jan. 1, 2024
A
near-infrared
light-driven
Janus
nanomotor
with
excellent
motility
and
collagenase
activity
is
constructed,
which
can
potently
penetrate
into
tumors
significantly
enhance
anti-tumor
immune
efficacy.
Biomaterials Science,
Journal Year:
2024,
Volume and Issue:
12(16), P. 4045 - 4064
Published: Jan. 1, 2024
With
the
increasing
research
and
deepening
understanding
of
glioblastoma
(GBM)
tumour
microenvironment
(TME),
novel
more
effective
therapeutic
strategies
have
been
proposed.
The
GBM
TME
involves
intricate
interactions
between
non-tumour
cells,
promoting
progression.
Key
goals
for
treatment
include
improving
immunosuppressive
microenvironment,
enhancing
cytotoxicity
immune
cells
against
tumours,
inhibiting
growth
proliferation.
Consequently,
remodeling
using
nanotechnology
has
emerged
as
a
promising
approach.
Nanoparticle-based
drug
delivery
enables
targeted
delivery,
thereby
specificity,
facilitating
combination
therapies,
optimizing
metabolism.
This
review
provides
an
overview
discusses
methods
nanotechnology.
Specifically,
it
explores
application
in
ameliorating
cell
immunosuppression,
inducing
immunogenic
death,
stimulating,
recruiting
regulating
metabolism,
modulating
crosstalk
tumours
other
cells.
Angewandte Chemie,
Journal Year:
2024,
Volume and Issue:
137(1)
Published: Aug. 23, 2024
Abstract
Chalcogens
are
used
as
sensitive
redox‐responsive
reagents
in
tumor
therapy.
However,
chalcogen
bonds
triggered
by
external
ionizing
radiation,
rather
than
internal
environmental
stimuli,
enable
site‐directed
and
real‐time
drug
degradation
target
lesions.
This
approach
helps
to
bypass
chemoresistance
global
systemic
toxicity,
presenting
a
significant
advancement
over
traditional
chemoradiotherapy.
In
this
study,
we
fabricated
hybrid
monodisperse
organosilica
nanoprodrug
based
on
homonuclear
single
(disulfide
(S−S,
approximately
240
kJ/mol),
diselenium
(Se−Se,
172
tellurium
(Te−Te,
126
kJ/mol)),
including
ditelluride‐bond‐bridged
MONs
(DTeMSNs),
diselenide‐bond‐bridged
(DSeMSNs)
disulfide‐bond‐bridged
(DSMSNs).
The
results
demonstrated
that
differences
electronegativities
atomic
radii
influenced
their
oxidation
sensitivities
reactivities.
Tellurium,
with
the
lowest
electronegativity,
showed
highest
sensitivity,
followed
selenium
sulfur.
DTeMSNs
exhibited
highly
responsive
cleavage
upon
exposure
X‐rays,
resulting
TeO
3
2−
.
Furthermore,
chalcogen‐hybridized
was
loaded
manganese
ions
(Mn
2+
)
enhance
release
of
Mn
during
radiotherapy,
thereby
activating
stimulator
interferon
genes
(STING)
pathway
enhancing
immune
response
inhibit
growth.
investigation
deepens
our
understanding
chalcogens
characteristics
radiotherapy
enriches
design
principles
for
nanomedicine
prodrugs.
Advanced Healthcare Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 5, 2025
Abstract
Poor
tumor
penetration
is
the
major
predicament
of
nanomedicines
that
limits
their
anticancer
efficacy.
The
dense
extracellular
matrix
(ECM)
in
one
barriers
against
deep
nanomedicines.
In
this
work,
a
slimming/excavating
strategy
proposed
for
enhanced
intratumoral
based
on
an
acid‐disassemblable
nanomicelles‐assembled
nanomedicine
and
NO‐mediated
degradation
ECM.
constructed
by
cross‐linking
nanomicelles,
which
are
self‐assembled
with
two
kinds
dendrimers
containing
phenylboronic
acid
lactobionic
acid,
through
borate
esterification.
acidic
microenvironment,
pH‐sensitive
ester
bonds
among
nanomicelles
hydrolyzed,
triggering
disassembly
(≈150
nm)
into
small
(≈25
nm).
response
to
over‐expressed
glutathione
(GSH),
NO
donor
loaded
produces
NO,
mediates
expression
metalloproteinases
ECM
tumor.
By
collaboration
disassembling
behavior
ECM,
designed
can
penetrate
long
distance
tumors.
will
provide
inspiration
overcoming
challenge
penetration.
Advanced Functional Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 4, 2025
Abstract
Cancer
immunotherapy,
which
leverages
the
body's
immune
system
to
combat
cancer,
offers
promise
of
lower
toxicity
and
higher
therapeutic
efficacy
compared
conventional
treatments.
However,
current
immunotherapeutic
approaches
face
significant
challenges
including
variable
patient
response,
immune‐related
adverse
events,
high
costs,
underscoring
urgent
need
for
innovative
strategies.
Metal‐based
nanomaterials
have
emerged
as
a
promising
avenue
in
cancer
immunotherapy
due
their
unique
physicochemical
properties
immune‐regulating
capabilities.
Despite
potential,
concerns
about
toxicity,
incomplete
understanding
modulation
mechanisms,
early‐stage
design
strategies
hinder
clinical
translation.
This
review
summarizes
recent
advancements
metal‐based
elucidates
mechanisms
by
they
enhance
antitumor
immunity
responses,
explores
potential
synergistic
effects
combining
multiple
metals.
We
also
discuss
key
future
perspectives
application,
aiming
provide
theoretical
foundation
development
immunotherapies
promote
broader
application
treatment.
Cellular and Molecular Neurobiology,
Journal Year:
2025,
Volume and Issue:
45(1)
Published: April 7, 2025
The
canonical
cyclic
GMP-AMP
(cGAMP)
synthase
(cGAS)-Stimulator
of
Interferon
Genes
(STING)
pathway
has
been
widely
recognized
as
a
crucial
mediator
inflammation
in
many
diseases,
including
tumors,
infections,
and
tissue
damage.
STING
signaling
can
also
be
activated
cGAS-
or
cGAMP-independent
manner,
although
the
specific
mechanisms
remain
unclear.
In-depth
studies
on
structural
molecular
biology
have
led
to
development
therapeutic
strategies
involving
modulators
their
targeted
delivery.
These
may
effectively
penetrate
blood-brain
barrier
(BBB)
target
multiple
central
nervous
system
(CNS)
diseases
humans.
In
this
review,
we
outline
both
non-canonical
pathways
activation
describe
general
associations
between
activity
CNS
diseases.
Finally,
discuss
prospects
for
delivery
clinical
application
agonists
inhibitors,
highlighting
novel
